Answers are grounded in this paper and cite their sources.
Japan has experienced 8 waves of coronavirus disease-2019 (COVID-19) with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants during the pandemic. The prevalent virus lineage (variant) was Wuhan type from the first to third waves, followed by Alpha in the fourth wave, Delta in the fifth wave, and Omicron from the sixth to eighth wave. The multiple waves of the pandemic differed in terms of clinical presentation. We herein present histopathology results focusing on bronchopulmonary findings in 9 autopsy cases of SARS-CoV-2 infection during the 8 waves of the pandemic in Japan. In the first 4 pandemic waves (non-Omicron phase), 6 autopsies were performed. Lung histology was consistent with diffuse alveolar damage (DAD) in all 6 cases (epithelial and/or vascular dominance pattern, n = 5; fibrotic dominance, n = 1). There were no differences in the histopathology of DAD between cases from the first 3 (Wuhan) waves ( n = 4) and those of the fourth (Delta) wave ( n = 2). In the seventh and eighth waves associated with the presumed Omicron BA.5 variant based on contemporaneous epidemiological data, DAD showed milder histology in all 3 cases with coexisting severe tracheitis observed in 2 out of 3 cases. Immunohistochemistry for SARS-CoV demonstrated abundant labeling in tracheal epithelia, but no or scarcely positive staining in pulmonary alveolar cells in all 3 cases. The copy number of SARS-CoV-2 RNA was measured in 1 case; the value was high in tracheal tissue but was extremely low in lung tissue obtained at autopsy. In a case with the Omicron variant, pre-existing nonspecific interstitial pneumonia was presumed to be exacerbated due to incidental SARS-CoV-2 infection after admission. Our case series provides information on less severe COVID-19-related lung injury following infection with the Omicron variants compared to the precedent lineages. Autopsies are invaluable for investigating pathophysiological differences and assessing therapeutic effects in potentially fatal infections with emerging new SARS-CoV-2 variants.
No takes yet. Share an insight, caveat, or question.
Mitomi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: